International Consensus Conference to Develop Improvement Criteria for Juvenile Dermatomyositis and Adult Dermatomyositis and Polymyositis: Workshop to Define Minimal Clinical Improvement and Major Clinical Response
Anticipated goals and use of results: We anticipate developing composite endpoints for future clinical trials that will be fully validated, endorsed by the ACR and EULAR, and used by all forthcoming myositis clinical trials and clinical studies as clinical endpoints. A likely secondary outcome of this work would be the stimulus to develop new therapies for myositis and conduct clinical trials of new therapeutic agents in myositis patients, given adequate ways to assess efficacy of new therapies in trials.
Hotel Novotel La Defense, Paris, France; Monday, June 09, 2014 – Tuesday, June 10, 2014
Contact: Dr. Sheila Newton (919) 541-4343